Portal de Periódicos da CAPES

Predictors of survival after resection of primary sarcomas of the chest wall—A large, single‐institution series

2018; Wiley; Volume: 118; Issue: 3 Linguagem: Inglês

10.1002/jso.25162

1096-9098

Jitesh B. Shewale, K. G. Mitchell, David B. Nelson, Anthony P. Conley, David C. Rice, Mara B. Antonoff, Wayne L. Hofstetter, Garrett L. Walsh, Stephen G. Swisher, Jack A. Roth, Reza J. Mehran, Ara A. Vaporciyan, Annikka Weissferdt, Boris Sepesi,

Ear and Head Tumors

Background and Objectives Chest wall sarcomas are rare and may demonstrate heterogeneous features. Surgery remains the mainstay of treatment with chemotherapy and radiotherapy used as adjuncts. Herein, we report outcomes of a large cohort of patients with primary chest wall sarcoma who underwent resection. Methods Records of 121 patients who underwent resection for primary chest wall sarcoma between 1998 and 2013 were reviewed. A thoracic pathologist reexamined all tumors and categorized them according to grade. Univariable and multivariable Cox analyses were conducted to identify predictors of overall survival (OS). Results The median age was 45.0 (range, 11‐81) years, and most tumors (63.6%, 77) were high grade. The median tumor size was 7 cm (range, 1‐21 cm). Fifty‐nine (48.8%) patients received neoadjuvant chemotherapy and 12 (9.9%) received neoadjuvant radiotherapy. A complete resection was achieved in 103 (85.1%) patients. Neoadjuvant chemotherapy ( P = 0.532) and radiation ( P = 1.000) were not associated with a complete resection. Five‐year OS among patients undergoing R0 and R1 resections was 61.9% and 27.8%, respectively. Multivariable analysis identified high grade (HR, 15.21; CI, 3.57‐64.87; P < 0.001), R1 (HR, 3.10; CI, 1.40‐6.86; P = 0.005), R2 resection (HR, 5.18; CI, 1.91‐14.01; P = 0.001), and age (HR, 1.02; CI, 1.01‐1.03; P = 0.002) as predictors of OS. Conclusions In this series of resected chest wall sarcomas, complete resection and tumor grade remain the most important survival predictors. Individual decisions are required for the utilization of neoadjuvant therapy.